argenex Stock Earnings Estimates Increased by HC Wainwright

argenex SE (NASDAQ:ARGX) – Equities researchers at HC Wainwright lifted their FY2026 EPS estimates for shares of argenex in a research note issued on Friday, October 23rd. HC Wainwright analyst D. Tsao now forecasts that the company will earn $27.76 per share for the year, up from their prior forecast of $26.27. HC Wainwright has a “Buy” rating and a $1,202.00 price target on the stock. The consensus estimate for argenex’s current full-year earnings is $25.79 per share. HC Wainwright also issued estimates for argenex’s Q4 2026 earnings at $7.13 EPS, Q1 2027 earnings at $6.54 EPS and FY2027 earnings at $33.52 EPS.

Several other brokerages have also recently issued reports on ARGX. Robert W. Baird lifted their price target on argenex from $823.00 to $861.00 and gave the company a “neutral” rating in a research report on Friday. Citizens Jmp upped their price objective on argenex from $932.00 to $1,200.00 and gave the company a “market outperform” rating in a report on Tuesday, August 18th. Wall Street Zen cut argenex from a “buy” rating to a “hold” rating in a research note on Sunday. UBS Group raised argenex from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $960.00 to $1,400.00 in a report on Wednesday, August 26th. Finally, Morgan Stanley lifted their target price on argenex from $1,140.00 to $1,190.00 and gave the stock an “overweight” rating in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $1,142.37.

argenex Price Performance

Shares of NASDAQ:ARGX opened at $869.33 on Tuesday. argenex has a 12 month low of $661.85 and a 12 month high of $1,072.75. The stock has a market cap of $54.67 billion, a price-to-earnings ratio of 30.33, a PEG ratio of 0.89 and a beta of 0.44. The stock’s 50 day moving average price is $953.35 and its 200 day moving average price is $853.01.

argenex (NASDAQ:ARGX) last released its quarterly earnings results on Friday, October 23rd. The company reported $7.80 EPS for the quarter, topping analysts’ consensus estimates of $7.44 by $0.36. argenex had a net margin of 31.66% and a return on equity of 47.70%. The company had revenue of $1.75 billion for the quarter.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ARGX. Oppenheimer & Co. Inc. grew its holdings in shares of argenex by 2.7% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 500 shares of the company’s stock worth $479,000 after acquiring an additional 13 shares during the last quarter. Park Avenue Securities LLC raised its position in shares of argenex by 157.4% during the third quarter. Park Avenue Securities LLC now owns 2,461 shares of the company’s stock worth $2,360,000 after purchasing an additional 1,505 shares during the period. Sigma Planning Corp purchased a new stake in shares of argenex during the third quarter valued at $1,027,000. Signaturefd LLC lifted its holdings in shares of argenex by 2.6% during the third quarter. Signaturefd LLC now owns 2,129 shares of the company’s stock valued at $2,041,000 after purchasing an additional 54 shares during the last quarter. Finally, BG Investment Services LLC acquired a new position in shares of argenex in the 3rd quarter valued at $1,397,000. Institutional investors own 60.32% of the company’s stock.

About argenex

argenx SE (NASDAQ: ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx’s lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.